Exicure, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jungsoo Kim
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2430 North Halsted Street Chicago IL United States of America 60614
- IPO Date
- May 22, 2018
- CIK
- 0001698530
- Website
- exicuretx.com
- Similar Companies
- Business
- Exicure, Inc. is a clinical-stage biotechnology company specializing in the development of nucleic acid therapies utilizing its proprietary Spherical Nucleic Acid (SNA) technology platform to deliver immunomodulatory and gene-regulating drugs. Its core products include GPC-100 (Burixafor), a drug candidate in Phase II clinical trials for stem cell mobilization in multiple myeloma and targeting blood cancers, and cavrotolimod (AST-008), a TLR9 agonist SNA immunotherapy for rare neurodegenerative diseases. The company focuses on therapies for inflammatory disorders, oncology, neurological conditions, and hair loss by enabling targeted delivery of nucleic acids to a broad range of tissues including brain, eyes, skin, and gut. Exicure operates primarily in the United States, with headquarters in Chicago, Illinois, and was founded in 2011. Recent major corporate developments include Exicure's acquisition of GPCR Therapeutics USA Inc., expanding its pipeline and intellectual property related to G-Protein Coupled Receptors and advancing GPC-100 through Phase II clinical trials with topline results expected in Q4 2025. The company is preparing for Phase III planning and investigating additional indications such as sickle cell disease and acute myeloid leukemia. Operationally, Exicure announced a significant reduction in workforce and the suspension of preclinical research in 2022 while focusing on out-licensing options for certain clinical assets to maximize shareholder value. Despite financial challenges and a Nasdaq compliance notice in 2025, Exicure continues strategic initiatives involving senior hires, clinical development, and potential collaborations in cell and gene therapy. The company was founded in 2011, initially in Evanston, Illinois, and has evolved through multiple financing rounds, a 2016 IPO, and strategic partnerships including a 2019 collaboration with AbbVie. Exicure's SNA technology distinguishes it by facilitating carrier-free cellular uptake of therapeutic nucleic acids, enhancing delivery efficiency and reducing systemic toxicity risks. The company maintains a focus on biopharmaceutical innovation targeting difficult-to-treat diseases via nucleic acid-based modalities while exploring strategic alternatives for corporate growth and value maximization. It conducts its discovery and development efforts primarily in its Chicago facility, leveraging internal capabilities and external partnerships.
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 42.7% in December
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial
This BlackRock stock just rocketed 70%
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Exicure, Inc. Reports Third Quarter 2025 Financial Results
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Exicure Posts Wider Loss in Fiscal Q2
Exicure, Inc. Reports Second Quarter 2025 Financial Results
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant